Assessment
tucatinib
HER2-positive locally advanced or metastatic breast cancer after at least 2 prior HER2-directed treatment regimens
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relationsAssessment
HER2-positive locally advanced or metastatic breast cancer after at least 2 prior HER2-directed treatment regimens
Connected evidence
2 relations